Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA commission report response will clarify structure/function claims, Kessler predicts.

This article was originally published in The Tan Sheet

Executive Summary

SUPPLEMENT HEALTH, STRUCTURE/FUNCTION CLAIMS DISTINCTION will be addressed by FDA in its upcoming response to the report from the President's Commission on Dietary Supplement Labels, David Kessler, MD, predicted at Hearst Magazines' Good Housekeeping consumer safety symposium on dietary supplements and herbal remedies in New York City March 3. The former FDA commissioner and now dean of Yale Medical School, predicted FDA's response will be to "do exactly what the Presidential Commission asked it to do," namely "help define where that line is between structure/function claims and health claims." Good Housekeeping held the symposium to generate discussion related to concerns over dietary supplements safety and efficacy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel